Search

Your search keyword '"Håkan-Bloch, Jonas"' showing total 17 results
Start Over Author "Håkan-Bloch, Jonas"
17 results on '"Håkan-Bloch, Jonas"'

6. Factors influencing the incidence of peristomal skin complications:Evidence from a multinational survey on living with a stoma

Author

Voegeli, David, Karlsmark, Tonny, Eddes, Eric Hans, Hansen, Helle Doré, Zeeberg, Rikke, Håkan-Bloch, Jonas, Hedegaard, Chris Juul, Voegeli, David, Karlsmark, Tonny, Eddes, Eric Hans, Hansen, Helle Doré, Zeeberg, Rikke, Håkan-Bloch, Jonas, and Hedegaard, Chris Juul

Abstract

Leakage of stomal effluents underneath the baseplate or inappropriate removal of stoma appliances can cause peristomal skin complications (PSCs), which are known to have many negative implications for people with a stoma. While numerous studies have examined the causes of PSCs, less is known about what drives the risk of a PSC developing. To address this gap in knowledge, the largest multinational survey to date was conducted, including 4235 people with a stoma on four continents and in 13 countries. The survey revealed that, besides leakage, other factors, such as age, gender, time since surgery and type of stoma, also drive the risk of PSCs. The survey also revealed that having a PSC resulted in greater use of stoma accessories and more frequent contact with health professionals, increasing overall healthcare costs. Collectively, the survey results reveal a need for more awareness on the risk factors for PSCs, which subsequently could have a positive effect on healthcare spending.

Published
2020

8. Patient-reported outcomes (PRO) from a randomized, crossover trial comparing insulin degludec using FlexTouch® with insulin glargine U100 using SoloSTAR® pen-injectors in patients with type 2 diabetes

Author

Warren, Mark L., Brod, Meryl, Håkan-Bloch, Jonas, Sparre, Thomas, and Chaykin, Louis B.

Abstract

Objective: Type 2 diabetes (T2D) is associated with insulin resistance and deteriorated glycemic control that can be restored with insulin injections. Choice of insulin pen-injector may affect complexity, adherence, efficacy of treatment and health-related quality of life. We describe detailed patient-reported outcomes (PROs) on treatment impact and preference comparing insulin degludec (degludec) using FlexTouch® versus insulin glargine U100 (glargine U100) with SoloSTAR® pen-injector. Methods: In this randomized, multicenter (USA), open-label, crossover, treat-to-target study (NCT01570751), patients with T2D using high-dose insulin (≥81 U/day from vials) were randomized (n = 145) 1:1 to 16 weeks of degludec U200 (3 mL FlexTouch®) followed by 16 weeks of glargine U100 (3 mL SoloSTAR®) or vice versa. PRO questionnaires assessed treatment impact and patient preference of pen-injectors. Results: Significantly more patients (p < 0.01) considered FlexTouch® ‘extremely easy’ for learning (62.5 vs. 43.0%), maintaining (63.2 vs. 42.2%), and adjusting the dose (63.2 vs. 44.4%), and significantly more were ‘very or extremely confident’ using the device (60.3 vs. 36.3%) and in its accuracy (50.7 vs. 30.4%) versus SoloSTAR®. Significantly more were ‘not at all bothered’ by device discomfort (74.3 vs. 54.1%), whereas device size (83.8 vs. 80.0%) or public use (69.9 vs. 60.7%) were numerically in favor of FlexTouch®. Significantly more patients preferred degludec treatment with FlexTouch® (59 vs. 22%), preferred to continue (67 vs. 15%) and recommend (67 vs. 14%) use of FlexTouch® compared with SoloSTAR® with glargine U100. Conclusions: In this randomized, crossover trial, lower treatment impact and higher patient preference were reported for FlexTouch® versus SoloSTAR® pen-injectors.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results